Results 71 to 80 of about 2,405,537 (303)

Highlights of 2024 - Print Issue

open access: yesPatient Safety
**The 2024 highlights issue of _Patient Safety_ is available to read online and download at no charge.** This issue highlights the Patient Safety Authority’s most-read articles from 2024, including original research, data analyses, safety ...
Patient Safety Authority
doaj   +1 more source

Facts and Controversies About Nurse Staffing Policy: A Look at Existing Models, Enforcement Issues, and Research Needs [PDF]

open access: yes, 2007
Examines state-mandated nurse-to-patient ratios as a policy model for solving staffing problems and ensuring patient safety and quality of care, as well as patient classification systems and pay-for-performance models.

core  

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Quality & Safety Update: Resident Teams Recognized, New Fellows Initiate Research [PDF]

open access: yes, 2017
Championing quality and safety is an institutional commitment and a critical part of day-to-day operations in the Department of Surgery. Scott Cowan, MD, FACS, Vice Chair for Quality in the Department, shares an update on current initiatives.

core   +1 more source

Precaution, governance and the failure of medical implants: the ASR(TM) hip in the UK [PDF]

open access: yes, 2014
Hip implants have provided life-changing treatment, reducing pain and improving the mobility and independence of patients. Success has encouraged manufacturers to innovate and amend designs, engendering patient hopes in these devices.
Joyce, Thomas   +2 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Around the World in 16 Ways: Searching Internationally for Fall Prevention Strategies

open access: yesPatient Safety, 2020
Pennsylvania fall rates have remained relatively steady over the past six years, ranging from 3.09–3.33 falls per 1,000 patient days. Other studies estimate that hospital falls occur at a rate of 3.56 per 1,000 patient days and 700,000 to 1 million ...
Caitlyn Allen, Susan C. Wallace
doaj   +1 more source

Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100+/- docetaxel. Comparison of efficacy and tolerability between lenograstim and pegfilgrastim [PDF]

open access: yes, 2015
Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared to daily administration of lenograstim in breast cancer patient undergoing adjuvant ...
Caruso, Davide   +9 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy